ApoE Gene Polymorphism and Clinical, Biochemical, and Sociodemographic Characteristics of Alzheimer's Disease Patients From Northern and Southern Regions of Kazakhstan Authors: Gulnaz Zholdasbekova, Aiym Kaiyrlykyzy, Aliya Kassenova, Dinara Alzhanova, Dmitry Klyuev, Sholpan Askarova Published: 2024 ABSTRACT ABSTRACTBackgroundAlzheimer's disease (AD) is the most frequent cause of dementia in seniors and is also one of the critical social issues of modern healthcare. Since AD is considered a multifactorial disease, the significance of particular risk factors in different ethnic populations is constantly reevaluated.MethodThe study group consisted of 181 patients with AD, and the control group included 244 healthy seniors comparable in sex and age to the dementia group. Our study compared clinical data, blood biochemical parameters, various sociodemographic characteristics, and ApoE gene polymorphism in patients diagnosed with AD from Kazakhstan's north (Astana city) and south (Almaty city) regions.ResultsIn our cohort, significant dementia‐associated variables included smoking, clinically significant depression, dyslipidemia, impaired glucose metabolism, insulin resistance, and liver dysfunction. Notably, AD patients had higher HDL levels, lower ALT levels, and higher total bilirubin and AST/ALT ratios. The ApoE ɛ4 genotype, a well‐known AD risk factor, was more prevalent in the northern AD group. Additionally, participants from Astana city had a higher incidence of strokes, potentially linked to elevated LDL levels, while Almaty city residents exhibited a higher prevalence of clinically severe depression.DiscussionThese findings underscore the importance of considering bio‐geographic and environmental factors in AD research. The study's outcomes may aid in further research and the development of personalized approaches for managing and treating AD in distinct geographical regions.Keywords: Alzheimer's, ApoE gene polymorphism, blood biochemical parameters, comorbid diseases, dementia Summary The study identifies key risk factors for dementia relevant to the Kazakhstani population, including smoking, clinically significant depression, dyslipidemia, impaired glucose metabolism, insulin resistance, and liver dysfunction. The study identifies key risk factors for dementia relevant to the Kazakhstani population, including smoking, clinically significant depression, dyslipidemia, impaired glucose metabolism, insulin resistance, and liver dysfunction. Alzheimer's patients in Kazakhstan exhibit biomarker patterns such as higher HDL levels, lower ALT levels, increased total bilirubin, and a higher AST/ALT ratio. Alzheimer's patients in Kazakhstan exhibit biomarker patterns such as higher HDL levels, lower ALT levels, increased total bilirubin, and a higher AST/ALT ratio. A notable prevalence of the ApoE ɛ4 genotype, a significant genetic risk factor for Alzheimer's, was observed, particularly in the northern regions of Kazakhstan. A notable prevalence of the ApoE ɛ4 genotype, a significant genetic risk factor for Alzheimer's, was observed, particularly in the northern regions of Kazakhstan. These insights underscore the importance of considering Kazakhstan's bio‐geographic and environmental factors in Alzheimer's disease research. These insights underscore the importance of considering Kazakhstan's bio‐geographic and environmental factors in Alzheimer's disease research. Introduction Alzheimer's disease (AD) is a progressive neurodegenerative disease and the most common cause of dementia in older adults. Around 50 million people worldwide had dementia in 2018; by 2050, that number is expected to rise to 150 million [1]. In Kazakhstan, as well as other countries, over the past decades, there has been an increase in the number of older adults. A recent pilot study on cognitive impairment revealed that the prevalence of mild cognitive impairment (MCI) is about 40% among the elderly population in Almaty City [2]. Since up to 30% of MCI develops into AD, we can approximate the prevalence of AD in Kazakhstan up to 15% among people aged 65 and over, projected to triple by 2050. However, despite the estimated high prevalence, the Kazakh population is not represented in global dementia studies. Besides, the World Alzheimer's Disease Reports states a constant lack of research on dementia in the Central Asian region [3]. APOE4 is only a very well‐studied gene strongly linked to the risk of late‐onset AD. The human form of APOE possesses three polymorphic alleles: E2, E3, and E4, and at least one copy of APOE‐ε4 is presented in around 60% of AD cases [4]. Although APOE4 polymorphism is widely recognized as a genetic risk factor for late‐onset AD, there are worldwide variations of APOE‐ε4 carriers by region and ethnicity [5]. For instance, a systematic literature review and meta‐analysis of the APOE4 prevalence in AD have demonstrated that AD patients recruited in Asian and southern European/Mediterranean communities seemed to have significantly lower E4 carrier status estimates (37% and 43%) than those recruited in North America (58%) or northern Europe (64%) [4]. However, the data on the distribution of APOE polymorphisms among AD patients in Central Asia and Kazakhstan is limited. The ideas about the significance of specific risk factors for AD development in different ethnic populations and geographic regions of the world are reviewed yearly, and further study is still a very urgent scientific and medical problem. Exposure to modifiable risk factors at the preclinical or moderate cognitive impairment stage may delay the beginning of irreversible neuronal death, leading to cognitive decline. Research into sociodemographic and comorbid risk factors for AD will allow the development of more efficient primary and secondary prevention strategies [6]. In this regard, in the present article, we have demonstrated the results of a pilot study to assess ApoE gene polymorphism and some clinical, biochemical, and sociodemographic characteristics of AD patients from northern (Astana city) and southern (Almaty city) regions of Kazakhstan. Materials and Methods Data Collection One hundred eighty‐one individuals diagnosed with AD and 244 cognitively normal controls were recruited from inpatient and outpatient treatment and prevention facilities in Astana and Almaty cities, Kazakhstan. Qualified neuropathologists experienced in dementia clinical diagnosis determined the diagnosis of potential AD according to the international criteria developed by the National Institute on Aging ‐Alzheimer's Association workgroups (NIA‐AA) 2011 [7]. For case selection, the following inclusion criteria were identified: (a) diagnosis of dementia due to AD; (b) age of 55 years and older at the time of diagnosis and data collection; and (c) voluntary consent to participate in the study. While our resources for employing a full range of neuroimaging biomarkers were limited, we could utilize MRI as a supplementary diagnostic tool. MRI provided critical insights into the structural brain changes associated with AD, which significantly supported our clinical evaluations and cognitive assessments. Brain MRI was performed in all patients with dementia to exclude other neurological causes that could lead to dementia, such as tumors, normotensive hydrocephalus, acute, and stroke. The following inclusion criteria were identified for control selection: (a) absence of cognitive and memory impairment, as determined through clinical evaluations by experienced neurologists and standardized cognitive tests; (b) voluntary consent to participate in the study. We excluded subjects with severe somatic diseases of the kidneys, liver, severe chronic obstructive pulmonary disease, cancer, and subjects with a mental disorder unrelated to AD. Written informed consent was obtained from all participants and their family members or caregivers (for demented individuals). Participants in both the study and control groups were surveyed using a sociodemographic questionnaire that covered education, place of birth, smoking, alcohol use, hypertension, heart disease, diabetes, head injury history, clinical depression, and hereditary dementia in first‐degree relatives. Blood samples were collected from all newly recruited participants during their visit. We then comprehensively analyzed clinical, laboratory, genetic, and sociodemographic parameters to compare the main and control groups. Additionally, we compared the same parameters between two different regions in Kazakhstan: Almaty in the south and Astana in the north. Blood Sample Collection and Biochemical Analyses The study participants were sampled fasting venous blood by qualified medical personnel in disposable plastic vacuum tubes with K2‐EDTA and coagulation activator gel. Blood samples were left to clot at room temperature for 30 min and then centrifuged for 10 min at 4000 rpm to prepare serum. Blood biochemical parameters were determined: total cholesterol, low and high‐density lipoproteins, triglycerides, C reactive protein, total and direct bilirubin, hepatic transaminases, glucose, and insulin. DNA Isolation and ApoE Genotyping DNA was isolated from the peripheral blood of patients with dementia and the control group using the DNeasy Blood & Tissue Kit (QIAGEN) according to the manufacturer's protocol. Quality and quantity were assessed using the spectrophotometric method on a NanoDrop‐2000 device and the fluorimetric method on a Qubit 2.0 device. Genotyping of the SNPs rs429358 and rs7412 in the APOE gene was based on the 5′‐nuclease assay, using polymerase chain reaction with specific TaqMan assay for each SNP (7500HT Real‐Time, Life Technology, Applied Biosystems). Statistical Analysis The quantitative variables were presented as the median and interquartile range (IQR). The comparison of qualitative data was performed using the chi‐squared test. Fisher's exact test was employed in cases where one or more cells had expected values less than 5. The Mann‐Whitney U test was used to compare, and the chi‐square test was used to analyze the distribution of APOE allele frequencies between AD patients and the control group. Binomial logistic regression was performed to ascertain the association between APOE4 ε4 carrier status and the risk of developing AD within the study's cross‐sectional design. The logistic regression model provides the odds ratio, a measure of association between the presence or absence of AD and APOE ε4 carrier status. Age and gender were included as covariates in the model to control for their potential confounding effects. Statistical significance was defined as a p‐value of equal or less than 0.05. The analyses and data visualization were conducted using standard statistical software, specifically R/RStudio. Results A Comparative Analysis of Sociodemographic Characteristics and Comorbidities in Patients With AD and Control Group A comparative analysis between groups was performed on 152 patients diagnosed with AD and the control group of 238 older adults without signs of dementia (Table 1). This study found a higher prevalence of women in both groups, with 71% in the AD group and 66.4% in the control group. Most participants were Kazakh, comprising 78.3% in the AD group and 73.5% in the control group. The control group had a significantly higher average body mass index (BMI) of 27.1 compared to 24.6 in the AD group (p < 0.05). The majority, 56.6% in the AD group and 48.7% in the control group, were from rural areas. Education levels were comparable, with most participants having secondary or higher education. Self‐reported depression was significantly more common in the AD group at 51.9%, compared to 30.2% in the control group (p < 0.05). No significant differences were found in chronic comorbidities or alcohol consumption between the groups. However, smoking was notably higher in the AD group at 34.9% compared to 20.2% in the control group (p = 0.006). TABLE 1Study participant's characteristics by disease status.ParametersAD n = 152Controls n = 238 p‐valueAge, years67 (63–72)67 (61.2–72)0. 705EthnicityKazakhs119 (78.3%)175 (73.5%)0.412Non‐Kazakhs (Slavic, other)33 (21.7%)63 (26.5%)GenderMale44 (29%)80 (33.6%)0.334Female108 (71%)158 (66.4%)ResidenceAstana city (north)84 (55.3%)169 (71%)0.001Almaty city (south)68 (44.7%)69 (29%)BMI24.6 (21.44–28.7)27.1 (24.1–30.1)< 0.001EducationPrimary/secondary44 (28.9%)56 (23.5%)0.419College/university108 (71.1%)182 (76.5%)Place of birthUrban66 (43.4%)122 (51.3%)0.729Rural86 (56.6%)116 (48.7%)Heart diseases (myocardial infarction, heart failure, and cardiac arrhythmias)42 (27.6%)72 (30.2%)0.274Hypertension91 (59.9%)117 (49.1%)0.073Stroke29 (19%)17 (7.1%)0.001Brain injury24 (15.8%)29 (12.2%)0.409Diabetes mellitus27 (11.3%)16 (10.5%)0.672Depression79 (51.9%)72 (30.2%)< 0.001Family history of dementia6 (3.9%)16 (6.7%)0.417MMSE score21 (13–23)29 (28–30)< 0.001Clock drawing test score4 (2–6)9 (9–10)< 0.001Former smoker53 (34.9%)48 (20.2%)0.006Alcohol consumption< 1 glass/do not drink.88 (57.9%)97 (40.7%)0.105One glass per week50 (32.9%)112 (47.1%)One bottle per week14 (9.2%)29 (12.2%)Heavy drinking16 (10.5%)10 (4.2%)0.089Total cholesterol, mmol/L4.84 (4.07–5.34)4.82 (4.15–5.7)0.421HDL, mmol/L1.37 (1.18–1.68)1.28 (1.02–1.56)0.034LDL, mmol/L3 (2.41–3.73)3.06 (2.49–3.67)0.976Triglycerides, mmol/L1.15 (0.85–1.46)1.33 (0.93–1.96)0.003Atherosclerotic index (LDL/HDL)2.77 (2–3.43)2.7 (2–3.7)0.456AST, IU/L18.2 (15.4–21.8)18.4 (15–24.0)0.488ALT, IU/L12.5 (9.2–17.5)15.8 (10.9–24.3)< 0.001AST/ALT ratio1.42 (1.06–1.84)1.16 (0.91–1.57)< 0.001C‐reactive protein, mg/L1.25 (0.4–3.6)1.6 (0.6–4)0.226Total bilirubin, μmol/L7.6 (5.7–9.9)6.6 (4.9–9.4)0.012Fasting glucose, mmol/L5.16 (4.59–5.87)4.76 (4.17–5.52)< 0.001Insulin, mIU/L9.3 (6.8–16.2)11.3 (7.35–19.9)0.133 Note: Data presented as median (Q 1–Q 3).Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; HDL, high‐density lipoprotein; LDL, low‐density lipoprotein. Study participant's characteristics by disease status. Note: Data presented as median (Q 1–Q 3). Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; HDL, high‐density lipoprotein; LDL, low‐density lipoprotein. A Comparative Analysis of Blood Biochemical Parameters in Patients With AD and Control Group In the study, blood biochemical parameters showed significant differences between dementia and control groups (Table 1). The dementia group had notably higher median HDL values at 1.37 compared to 1.28 in the control group (p = 0.034). Triglyceride levels were lower in the dementia group at 1.15 versus 1.33 in the control group (p = 0.003). ALT levels were significantly lower in the dementia group, with a median of 12.5, against 15.8 in the control group (p < 0.001), while AST levels showed no significant difference. The dementia group also had a higher AST/ALT ratio (1.42 vs. 1.16). Total bilirubin levels were higher in the dementia group at 7.06, compared to 6.6 in the control group (p = 0.012). No significant differences between the groups were observed in CRP or insulin levels. However, glucose levels were higher in the AD group at 5.16, compared to 4.76 in the control group (p < 0.001). A Comparative Analysis of Comorbidities and Blood Biochemical Parameters in Patients With AD Between Almaty and Astana The study revealed significant regional differences in comorbidities among AD patients in Almaty (n = 68) and Astana (n = 84) (Table 2). In Astana, 7.4% of AD patients reported a family history of dementia, compared to none in Almaty, indicating a higher hereditary prevalence in the north (p = 0.031, Figure 1). Depression history was significantly more common in Almaty at 62.3% versus 29.6% in Astana (p = 0.004, Figure 1). Stroke prevalence was higher in the north, with 50% in Astana compared to 4% in Almaty (p < 0.001). No significant differences were found in arterial hypertension, heart disease, diabetes mellitus, or traumatic brain injury history. TABLE 2Comorbidities of AD patients by region.Astana (n = 84)Almaty (n = 68) p‐valueHypertension, yes (%)53 (63.1)38 (55.9)0.420Diabetes, yes (%)12 (14.3)4 (5.9)0.108Heart disease, yes (%)25 (29.8)17 (25.0)0.487Stroke, yes (%)27 (32.1)2 (2.9)< 0.05Family history of dementia, yes (%)15 (17.9)0< 0.05Brain injury, yes (%)11 (13.1)13 (19.1)0.616Depression, yes (%)16 (19.0)40 (58.8)< 0.05 Comorbidities of AD patients by region. Blood parameters of the subjects with AD in Almaty and Astana cities (Fisher's exact test, *p < 0.05, **p < 0.01). Biochemical analysis showed regional variations in AD patients' LDL, glucose, and insulin levels (Figure 1). LDL levels were higher in Astana, with a median of 3.46 versus 2.8 in Almaty (p = 0.0431). Glucose levels were higher in Almaty, with median values of 5.33 compared to 4.61 in Astana (p = 0.0019). Insulin levels were also higher in Almaty, at a median of 10.3 versus 7.5 in Astana (p = 0.009). No significant regional differences were observed in ALT, AST, total bilirubin, triglycerides, HDL cholesterol, and CRP. Apolipoprotein E Genotype and Allele Frequencies Apolipoprotein E genotype and allele frequencies were analyzed on 162 AD patients and 206 controls. The distribution of various APOE genotypes in the study population was analyzed between individuals with AD and a control group without the disease (Table 3). The data shows that the control group had a higher proportion of individuals with the e3/e3 genotype than the AD group. Meanwhile, the AD group had a notably higher percentage of individuals with the e3/e4 and e4/e4 genotypes, often associated with a higher risk of developing AD. TABLE 3Apolipoprotein E genotype and allele frequency distributions in AD and control groups.AD (n = 162)Control (n = 206)Genotypee2/e21.23%1.46%e2/e34.94%4.37%e2/e40.62%0.97%e3/e352.47%68.45%e3/e431.48%22.82%e4/e49.26%1.94%Allele frequencyE24.1%4.2%E370.6%82%E425.3%13.8% Apolipoprotein E genotype and allele frequency distributions in AD and control groups. The chi‐square analysis of APOE allele frequencies in AD and control groups showed a similar distribution of APOE2 allele in both AD and control groups (Table 3). Precisely, 4.1% of individuals in the AD group and 4.2% in the control group were carriers. Statistical comparison using a chi‐square test revealed no significant disparity in the APOE2 allele frequencies between the two groups (χ 2 = 0.001, p = 1.0). In contrast, the distribution pattern of the APOE3 allele showed differences between groups. While 70.6% of the AD group harbored this allele, a notably higher proportion, 82%, was observed in the control group. The chi‐square test emphasized the statistical significance of this variation, returning χ 2 = 12.59 (p = 0.0004). The APOE4 allele, often linked with a heightened risk for AD, was more prevalent among the AD group at 25.3%, compared to only 13.8% in the control group. The chi‐square analysis for this allele solidified its significance with an χ 2 value of 14.84 and a p‐value of 0.00012 (Table 3). APOE ε4 carriers have approximately 1.9 times the odds of having AD compared to Non‐ε4 carriers (95% CI 1.25–3.16, p = 0.00247) after controlling for age and gender. However, in examining the regional variations in the risk of AD, our study shows distinct patterns between the Astana and Almaty regions. Specifically, the prevalence of the APOE ε4 allele was higher among AD patients in the northern region, with a rate of 32.3% in Almaty compared to 48.3% in Astana (p = 0.04). Furthermore, in the Astana region, individuals carrying the APOE ε4 allele were found to be significantly more susceptible to AD, with an odds ratio of 2.78 (95% CI: 1.23–4.61, p = 0.0005), indicating a notably higher risk compared to non‐carriers of the allele. Conversely, in the Almaty region, while APOE ε4 carriers exhibited an increase in the odds of developing AD compared to non‐carriers, this elevation in risk did not reach statistical significance after adjusting for age and gender (Figure 2). Forest plot of the association between APOE ε4 carrier status and AD risk overall and by regions (Astana and Almaty). Discussion APOE4 is only a very well‐studied gene strongly linked to the risk of late‐onset AD, and there are worldwide variations of APOE‐ε4 carriers by region and ethnicity. Our study analyzed the apolipoprotein E genotype and allele frequencies on 162 AD patients and 206 controls residing in Kazakhstan's northern (Astana city) and southern (Almaty city) regions. In our cohort, 25.3% of people with AD were carriers of the APOE ε4 gene, compared with 13.8% in the non‐dementia group. In addition, the APOE ε4 allele was more frequent among AD patients in the northern region. The statistical significance of these differences suggested a gradient in the frequency of the ApoeE4 genotype from south to north. Our results are consistent with the data of previous studies, which also show a noticeable gradient in the frequency of the ApoeE4 genotype from south to north. According to this research, the proportion of people carrying the ApoeE4 gene is between 10% and 15% in the south and 40% and 50% in the north [8]. As a result, our data both support and extend earlier research findings, showing that the frequency of the ApoeE4 genotype varies geographically across the northern and southern regions. This gradient in the frequency of the apoE4 genotype could be explained by differences in the population's genetic composition across different geographic areas and potential environmental interactions and risk factors. The association between APOE genotype and AD has been a consistent topic of interest in genetic epidemiological studies. Our findings further validate the role of the APOE ε4 allele in the etiology of AD and offer a nuanced understanding of its distribution across different populations. Region‐wise, our data demonstrates intriguing variability. The pronounced risk associated with the APOE ε4 allele in Astana emphasizes the potential interplay of genetic predispositions and region‐specific environmental or lifestyle factors. Such factors might modulate the genetic risk and should be a focal point of future investigations. In contrast, the Almaty region's data suggests a more tempered effect of the APOE ε4 allele, indicating potential regional heterogeneities in genetic risk. However, it is essential to note that research on the effects of environmental factors on the onset of AD has not been sufficiently undertaken in nations with limited resources, and findings are scarce. According to research, smoking increases the likelihood of developing AD and cognitive decline. The US National Institutes of Health has identified smoking as a risk factor for AD and cognitive impairment [9]. Early case‐control studies suggested a link between smoking and a lower risk of AD; however, a meta‐analysis of 19 prospective studies discovered a significant connection between current smoking and a higher risk of dementia [10]. Some longitudinal studies note that people who have never smoked have a lower risk of developing AD [10, 11]. The risk of dementia, AD, or diabetes mellitus has also not been linked to lifetime tobacco usage [12]. In our cohort, former smokers predominated in the group of AD patients. However, it should be noted that there is insufficient evidence linking smoking to an increased risk of dementia. There is no difference in dementia risk between non‐smokers, current smokers, and ex‐smokers, according to some research [12]. In addition, the data are difficult to interpret due to the competing risk of death among smokers, which can lead to them dying before the age of dementia [13]. Besides, the inconsistent results may be due to accounting for past smoking in study participants and selective smoking cessation later in life. A possible connection between depression and AD has been suggested by epidemiological research and systematic reviews. As indicated by several studies, depression can both be a risk factor and a prodromal indication for the onset of dementia. Other studies suggest that AD and depression may start simultaneously or shortly after that [14, 15]. A history of depression may be linked to an approximately two‐fold increased risk of dementia, according to a meta‐analysis of 13 research [16]. Our study showed a statistically significant difference between the disease and control groups regarding depression. It underlines how crucial it is to take depression into account as an essential risk factor and possibly an early indication of AD. Furthermore, we observed regional disparities in depression rates among AD patients, with higher rates in the southern region. However, it is essential to note that our study did not employ specific diagnostic methods for depression, making it challenging to definitively conclude a significant difference in depression prevalence between Almaty and Astana. Various factors, including psychosocial conditions, chronic illnesses, and sleep disturbances, can contribute to depression risk, which was beyond the scope of our investigation. Our study relied on subjective data for depression assessment. Given the limited population‐based research on this topic in Kazakhstan, we cannot provide a robust evaluation of depression prevalence among AD patients across the country. Comprehensive future research efforts are needed to understand this issue better. In addition, we have found that among AD patients, glucose and insulin levels were significantly higher in Almaty. In contrast, the level of LDL and the prevalence of stroke were significantly higher in Astana. It is consistent with earlier research that connected LDL cholesterol to cardiovascular atherosclerosis [17, 18]. These findings underline the significance of metabolic factors linked to diabetes, cardiovascular diseases, and atherosclerosis in the onset of dementia. It is possible that climatic factors, such as low ambient temperature, also play a role in the risk of ischemic stroke and intracerebral hemorrhage [19]. However, additional research is still required to confirm these connections. A correlation between plasma HDL cholesterol levels, plasma triglycerides, and the risk of dementia and AD has also been shown [20, 21, 22]. High HDL cholesterol levels have been associated with the brain's accumulation of neurofibrillary tangles and plaques [21]. Additionally, more significant plasma HDL cholesterol levels have been linked to a higher risk of dementia from all causes and AD [22]. In comparison, greater plasma triglyceride concentrations are linked to a higher risk of non‐AD [20]. Our study found differences in plasma HDL and triglyceride levels between a group of dementia patients and a control group: the AD group had higher HDL values and lower triglyceride levels. There is currently a growing amount of data suggesting a connection between liver function, metabolic problems, and AD. The malfunction of metabolites such as amino acids, phosphatidylcholines, and lipids may be impacted by altered liver enzymes [23], which may, in turn, influence the pathophysiological features of AD [24]. According to previously published reports, the levels of liver enzymes, including alanine aminotransferase (ALT) and aspartate aminotransferase (AST), were significantly lower in AD patients and were strongly associated with cognitive impairment [25]. Low plasma aminotransferase levels have been associated with an increased risk of dementia [25]. In our cohort, we also discovered differences in liver biochemical parameters between a group of AD patients and a control group. In particular, we found that the ALT levels were lower while the total bilirubin level was higher in the dementia group. Our study also discovered differences in the AST/ALT ratio between AD patients and a control group. The higher value of this ratio is associated with altered liver functions [26] and an increased risk of cognitive impairment [25]. According to findings of earlier investigations, the AST/ALT ratio was higher, and the ALT level was lower in the AD group than in healthy individuals [27]. Bilirubin levels between AD patients and healthy controls are greater in AD patients in some studies [28] and are identical in other research [27]. Nevertheless, the differences in liver biochemical parameters that we found between AD and a control group could be due to other causes unrelated to the onset of dementia, and, therefore, more research is needed to fully comprehend the functions of the liver in the onset and progression of dementia. The main limitation of our study is the relatively small sample size, which, while significant considering the scarcity of population‐based research in Central Asia, may limit the detection of genetic associations and region‐specific risk factors. Additionally, we could not employ a comprehensive set of neuroimaging biomarkers due to limited resources, but we could use MRI as an additional diagnostic tool. MRI offered valuable information on the structural brain changes linked to AD, greatly complementing our clinical evaluations and cognitive assessments. This improved our diagnostic accuracy despite the absence of more advanced biomarker data. The limitations are mainly attributed to the fact that the diagnosis of AD was officially recognized in Kazakhstan in 2015, and there are no population‐based studies in the country. In addition, the country's two largest cities (Almaty and Astana) only have the necessary resources and qualified medical personnel capable of making a reliable diagnosis of AD. As mentioned previously, there is a constant lack of research on dementia in Central Asia, and, to date, this is the first comprehensive report of the AD cohort in the region. A larger cohort would provide greater statistical power and enhance the ability to identify subtler associations. As a result, caution should be exercised when generalizing these results to broader populations or other regions. We recommend that future research endeavors with larger, more diverse cohorts be conducted to confirm our findings and potentially uncover additional risk factors pertinent to this population. In summary, understanding AD as a long‐term pathophysiological process that precedes clinical symptoms is a modern paradigm in the study of this disease. This process can take years, even decades, before dementia's obvious clinical signs start to surface. Besides, studies on the etiology and pathophysiology of AD strongly suggest that this disease is multifactorial, with the hereditary and environmental factors contributing to its onset and progression. However, the question about the significance of specific risk factors of AD for people of different ethnicities residing in various geographic regions is still open. Our study of the clinical, biochemical, and sociodemographic characteristics of AD patients from northern and southern areas of Kazakhstan found significant differences in these patients' features. In particular, our data suggest that altered glucose metabolism may increase the risk of developing AD in southern regions. In contrast, APOE ε4 genotype, cholesterol metabolism, and subsequent cardiovascular events increase the risk of developing AD in people living in colder climatic conditions. Although our study has several limitations, our results further highlight the importance of considering biogeographical and environmental elements when studying this disease. In various regions, these discoveries may facilitate additional research and the formulation of individualized strategies for managing and treating AD and related dementias. Author Contributions Conceptualization, S.A.; funding acquisition, S.A., A.A.; investigation, G.Z., A.K., D.A.; supervision, S.A.; writing–original draft, G.Z., A.K., S.A.; writing–review and editing, S.A., A.K., D.K.. All authors have read and agreed to the published version of the manuscript. Ethics Statement The study was conducted under the Declaration of Helsinki and approved by the Local Ethic Committee of National Laboratory Astana (No. 05–2020, dated 24.09.2020). Written informed consent was obtained from each participant and their caregivers. Conflicts of Interest The authors declare no conflicts of interest. Acknowledgments This work has been funded by the Ministry of Education and Science of the Republic of Kazakhstan (Funder Project Reference: AP14871338) and Nazarbayev University under Collaborative Research Program Grant No. 20122022CRP1602. Funding: This work has been funded by the Ministry of Education and Science of the Republic of Kazakhstan (Funder Project Reference: AP14871338) and Nazarbayev University under Collaborative Research Program Grant No 20122022CRP1602. Data Availability Statement The data supporting this study's findings are available from the corresponding author upon reasonable request. References Associated Data Data Availability Statement The data supporting this study's findings are available from the corresponding author upon reasonable request.